05/19/2017 Physiogenex and CLEA Japan Inc. present the benefits of SGLT2 inhibitor dapagliflozin on their 10-week rat model for evaluating drugs targeting Diabetic Nephropathy at EDNSG 2017 in Helsinki
Through their partnership put in place in January 2016,
Physiogenex and CLEA Japan Inc. have worked thoroughly to set-up and validate a novel rat model for evaluating drugs targeting Diabetic Nephropathy.
The Spontaneously Diabetic Torii fatty (SDT fatty) rat, a model of obesity type 2 diabetes distributed by CLEA Japan Inc. since 2012, has been optimized to fit with preclinical requirements for developing drugs targeting Diabetic Nephropathy.
Within only 10 weeks, this obese and diabetic rat model develops advanced kidney complications, with a >50% glomerular filtration rate (GFR) decline.
Dr. François Briand, Director of Research and Business Development at Physiogenex, will present the study during the 30th Annual Meeting of the European Diabetic Nephropathy Study Group (EDNSG) in Helsinki. The abstract will be presented during the oral abstracts session 5 (Experimental Diabetic Nephropathy: in vivo aspects) on Saturday May the 20th, 2017.
If you wish to know more about the SDT fatty rat model for Diabetic Nephropathy for setting-up a drug evaluation, ask Physiogenex experts
If you wish to know more about the SDT fatty rat model for obesity/type 2 diabetes, contact CLEA Japan Inc
About CLEA Japan, Inc.
CLEA Japan, Inc. is the expert supplier of experimental rodents, constantly providing best quality bioservices to researchers. Based on its experience acknowledged by pharmaceutical companies, CLEA Japan, Inc. will efficiently provide CRO services with Physiogenex.
Find out more about CLEA Japan, Inc. and the services offered
Physiogenex is a leading preclinical research organization providing non clinical services in metabolic disorders and complications. We offer in vivo translational diseases models as well as ex vivo assays to support efficacy and pharmacological assays. We focus on metabolic diseases, diabetes, insulin resistance, obesity, dyslipidemia, liver diseases (NASH to fibrosis) and renal complications.
Please visit our website for more information